Alzheimer’s disease currently affects over 5.5 million Americans and is projected to quadruple by 2050. Currently available therapeutics are only able to slow the progression of Alzheimer’s by a few months, are not disease modifying and therefore unable to prevent or reverse the disease.
Alzeca’s goal is to develop the best-in-class imaging compound to diagnose Alzheimer’s disease at the earliest stages. Early detection of Alzheimer’s is critical as disease pathology begins to accumulate 10+ years prior to cognitive onset of the disease. As a result, early detection of Alzheimer’s pathology offers the patient an opportunity to take counteractive measures at a point where the disease may still be treatable.
Early and accurate detection of Alzheimer’s disease pathology will enable: 1) Drug therapies to be more effective, 2) Improved screening of Alzheimer’s patients for drugs under clinical development, and 3) Improved lifestyle planning for patients and family members affected by Alzheimer’s.